So far, most Wnt signaling inhibitors are directed against components acting upstream of APC (e.g., frizzled receptors, R-spondin 3, and porcupine), and are therefore unlikely to be effective in CRC, where APC is frequently mutated [154]. This evidence concerns the gene APC and colorectal carcinoma.